Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges
Six former Insys executives and managers arrested on changes of misleading insurers and pharmacy benefit managers into authorizing payments for Subsys sublingual fentanyl pain medicine.
You may also be interested in...
Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.
Settlement with US government also includes $225m payment to resolve criminal and civil cases related to illegal marketing of the sublingual fentanyl spray Subsys.
Bellwether trial set to begin in September after judge says cities may be able to recover damages for cost of governmental services that are the result of defendants' alleged conduct.